286 related articles for article (PubMed ID: 21884695)
1. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma.
Huang ZH; Hu Y; Hua D; Wu YY; Song MX; Cheng ZH
Exp Mol Pathol; 2011 Dec; 91(3):702-7. PubMed ID: 21884695
[TBL] [Abstract][Full Text] [Related]
2. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma.
Hua D; Hu Y; Wu YY; Cheng ZH; Yu J; Du X; Huang ZH
Exp Mol Pathol; 2011 Aug; 91(1):455-60. PubMed ID: 21600201
[TBL] [Abstract][Full Text] [Related]
3. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
4. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients.
Chang H; Yi B; Li L; Zhang HY; Sun F; Dong SQ; Cao Y
Exp Mol Pathol; 2008 Oct; 85(2):96-100. PubMed ID: 18691570
[TBL] [Abstract][Full Text] [Related]
5. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.
Lee S; Lee HJ; Kim JH; Lee HS; Jang JJ; Kang GH
Am J Pathol; 2003 Oct; 163(4):1371-8. PubMed ID: 14507645
[TBL] [Abstract][Full Text] [Related]
6. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?
Mohamed NA; Swify EM; Amin NF; Soliman MM; Tag-Eldin LM; Elsherbiny NM
Arab J Gastroenterol; 2012 Sep; 13(3):111-5. PubMed ID: 23122451
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
Moribe T; Iizuka N; Miura T; Stark M; Tamatsukuri S; Ishitsuka H; Hamamoto Y; Sakamoto K; Tamesa T; Oka M
Int J Oncol; 2008 Nov; 33(5):949-58. PubMed ID: 18949357
[TBL] [Abstract][Full Text] [Related]
8. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
9. The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.
Tsunedomi R; Ogawa Y; Iizuka N; Sakamoto K; Tamesa T; Moribe T; Oka M
Int J Oncol; 2010 Jan; 36(1):205-12. PubMed ID: 19956849
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
Shih YL; Shyu RY; Hsieh CB; Lai HC; Liu KY; Chu TY; Lin YW
Cancer; 2006 Aug; 107(3):579-90. PubMed ID: 16795071
[TBL] [Abstract][Full Text] [Related]
11. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
12. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
[TBL] [Abstract][Full Text] [Related]
13. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma.
Li B; Liu W; Wang L; Li M; Wang J; Huang L; Huang P; Yuan Y
Ann Surg Oncol; 2010 Jul; 17(7):1917-26. PubMed ID: 20112070
[TBL] [Abstract][Full Text] [Related]
15. Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma.
Tsutsui M; Iizuka N; Moribe T; Miura T; Kimura N; Tamatsukuri S; Ishitsuka H; Fujita Y; Hamamoto Y; Tsunedomi R; Iida M; Tokuhisa Y; Sakamoto K; Tamesa T; Sakaida I; Oka M
Clin Chim Acta; 2010 Apr; 411(7-8):516-20. PubMed ID: 20064498
[TBL] [Abstract][Full Text] [Related]
16. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
18. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma.
Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L
Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889
[TBL] [Abstract][Full Text] [Related]
19. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications.
Xu B; Di J; Wang Z; Han X; Li Z; Luo X; Zheng Q
Biochem Biophys Res Commun; 2013 Aug; 438(2):324-8. PubMed ID: 23891693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
